Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia

Leukemia and Lymphoma

Volumn 45, Issue 11, 2004, Pages 2215-2219

  Orlowski, Robert Z ^a,c   Mills, Sharon R ^a   Hartley, Eric E ^a   Ye, Xiaobu ^a,b   Piantadosis, Steven ^a,b   Ambinder, Richard F ^a   Gore, Steven D ^a   Miller, Carole B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Oncology Biostatistics   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Herpes simplex; Leukemia; Prophylaxis; Reactivation; Valacyclovir

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; VALACICLOVIR;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROAT CULTURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS REACTIVATION;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; HERPES SIMPLEX; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; SIMPLEXVIRUS; TIME FACTORS; VALINE;

EID: 8644225734     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001733763     Document Type: Article

References (25)

1. Wingard, J.R. (1993) "Viral infections in leukemia and bone marrow transplant patients", Leukemia & Lymphoma 11, 115-125.
2. Devine, S.M. and Wingard, J.R. (1994) "Viral infections in severely immunocompromised cancer patients", Supportive Care in Cancer, 2, 355-368.
3. Reusser, P. (1998) "Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients", Supportive Care in Cancer, 6, 39-45.
4. Meyers, J.D., Wade, J.C., Mitchell, C.D., Saral, R., Lietman, P.S., Durack, D.T., et al. (1982) "Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host", The American Journal of Medicine, 73, 229-235.
5. Saral, R., Burns, W.H., Laskin, O.L., Santos, G.W. and Lietman, P.S. (1981) "Acyclovir prophylaxis of herpes-simplex-virus infections", The New England Journal of Medicine, 305, 63-67.
6. Hann, I.M., Prentice, H.G., Blacklock, H.A., Ross, M.G., Brigden, D., Rosling, A.E., et al. (1983) "Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial", British Medical Journal, 287 384-388.
7. Saral, R., Ambinder, R.F., Burns, W.H., Angelopulos, C.M., Griffin, D.E., Burke, P.J., et al. (1983) "Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study", Annals of Internal Medicine, 99, 773-776.
8. Prentice, H.G. and Hann, I.M. (1983) "Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir", Schweizerische Medizinische Wochenschrift Supplementum, 14, 26-29.
9. Anderson, H., Scarffe, J.H., Sutton, R.N., Hickmott, E., Brigden, D. and Burke, C. (1984) "Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial", British Journal of Cancer, 50, 45-49.
10. Engelhard, D., Morag, A., Or, R., Naparstek, E., Cividalli, G., Ruchlemer, R., et al. (1988) "Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts", Israeli Journal of Medical Science, 24 145-150.
11. Lonnqvist, B., Palmblad, J., Ljungman, P., Grimfors, G., Jarnmark, M., Lerner, R., et al. (1993) "Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden", Supportive Care in Cancer, 1, 139-144.
12. Heimdahl, A., Mattsson, T., Dahllof, G., Lonnquist, B. and Ringden, O. (1989) "The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 68, 711-716.
13. Bergmann, O.J., Ellermann-Eriksen, S., Mogensen, S.C. and Ellegaard, J. (1995) "Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial", British Medical Journal, 310, 1169-1172.
14. Bergmann, O.J., Mogensen, S.C., Ellermann-Eriksen, S. and Ellegaard, J. (1997) "Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial", Journal of Clinical Oncology, 15, 2269-2274.
15. Leflore, S., Anderson, P.L. and Fletcher, C.V. (2000) "A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections", Drug Safety, 23, 131-142.
16. Wagstaff, A.J., Faulds, D. and Goa, K.L. (1994) "Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy", Drugs, 47, 153-205.
17. Farah, R.A., Aquino, V.M., Munoz, L.L. and Sandler, E.S. (1998) "Safety and cost-effectiveness of outpatient total body irradiation in pediatric patients undergoing stem cell transplantation", Journal of Pediatric Hematology/Oncology, 20, 319-321.
18. Ruiz-Arguelles, G.J., Gomez-Almaguer, D., Ruiz-Arguelles, A., Gonzalez-Llano, O., Cantu, O.G. and Jaime-Perez, J.C. (2001) " Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens", American Journal of Hematology, 66, 241-244.
19. Acosta, E.P. and Fletcher, C.V. (1997) "Valacyclovir", Annals of Pharmacotherapy, 31, 185-191.
20. Stein, G.E. (1997) "Pharmacology of new antiherpes agents: famciclovir and valacyclovir", Journal of the American Pharmaceutical Association (Washington), NS37, 157-163.
21. CTEP, NCI (1999) Common toxicity criteria manual, version 2.0. Pp 1-35. Bethesda: National Cancer Institute.
22. Khan, S.A. and Wingard, J.R. (2001) "Infection and mucosal injury in cancer treatment", Journal National Cancer Institute Monographs, 29, 31-36.
23. Bell, W.R., Chulay, J.D. and Feinberg, J.E. (1997) "Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204)", Medicine (Baltimore), 76, 369-380.
24. Rivaud, E., Massiani, M.A., Vincent, F., Azoulay, E. and Coudrec, L.J. (2000) "Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient", Archives of Internal Medicine, 160, 1705-1706.
25. Rayani, S.A., Nimmo, C.J., Frighetto, L., Martinusen, S.M., Nickoloff, D.M., Reece, D.E., et al. (1994) "Implementation and evaluation of a standardized herpes simplex virus prophylaxis protocol on a leukemia/bone marrow transplant unit", Annals of Pharmacotherapy 28, 852-856.